Skip to content

Comparison of the efficacy and safety of precise devascularization of gastric varices under ultrasound endoscopy-guided approach and endoscopic direct sclerotherapy for the treatment of gastric varices: A prospective case-control study

Comparison of the efficacy and safety of precise devascularization of gastric varices under ultrasound endoscopy-guided approach and endoscopic direct sclerotherapy for the treatment of gastric varices: A prospective case-control study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117678
Enrollment
Unknown
Registered
2026-01-27
Start date
2025-03-24
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric varices

Interventions

EUS-guided precise ligation procedure:EUS-guided injection of tissue glue/spring coils into the GVs was performed. If moderate to severe EVs were present simultaneously, esophageal variceal ligation w
Endoscopic direct sclerotherapy:For obvious GVs, puncture needle injection of glyoxalate + tissue glue is performed. If moderate to severe EVs are present simultaneously, esophageal variceal ligation

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18 - 75 years old; 2. Cirrhosis (diagnosed through imaging, laboratory tests, clinical symptoms or liver biopsy); 3. Had acute rupture and bleeding of GVs (GOV1, GOV2 or IGV1) or previous rupture and bleeding (bleeding lesions observed under endoscopy originated from GVs or no other bleeding lesions were found except GVs); 4. Had occult GVs (i.e., not visible under traditional white light endoscopy, but visible under EUS); 5. Was willing to participate in this clinical study, complied with the study requirements and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Suffering from advanced liver cancer or other malignant tumors with an expected lifespan of less than 3 months; 2. Complicated with severe diseases in other organs such as the heart, lungs, and kidneys.

Design outcomes

Primary

MeasureTime frame
The rates of all-cause rebleeding and bleeding-related mortality over a period of 6 weeks and 1 year;

Secondary

MeasureTime frame
Incidence rate of operation-related adverse events;Hospitalization period;The rate of second endoscopic hemostasis;Success rate of endoscopic treatment;The incidence of other complications related to portal hypertension;

Countries

China

Contacts

Public ContactWang Zhu

West China Hospital, Sichuan University

88490065@qq.com+86 189 8060 2897

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026